Should I buy Kyndryl (KD) stock or is it too late?

Kyndryl · Information Technology · price $13

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: JP Morgan — 63% of its targets hit on this sector (166 calls tested). It aims for $14 (+5.7 %), call made on August 11, 2026, maturing on August 11, 2027 (17 d ago).

The 1 reliable analyst $14+5.7 %

The 4 other firms $14+5.7 %

How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $14 median. “The 4 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Kyndryl

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Susquehanna	40 %	-0.1 %	5	$13 -2%
Oppenheimer	20 %	-32.2 %	5	$55 +315%

In short — Should you invest in Kyndryl? Is it too late, still worth it? Analysts are split (0% buy, median target $14, i.e. +6%), and the most reliable on KD targets even higher. But the stock is volatile, it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on KD, Scotiabank (100% hit rate, 3 scored calls), targets $15 (call made on May 8, 2026, maturing on May 8, 2027) (+13%) in its most recent call.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 5 ratings, 4 are neutral and 1 is a sell.
Limited upside: the median target is only +6% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Volatile stock: sharp swings — including steep drops — are part of its profile.
No dividend: your return depends only on price appreciation.

The analyst consensus on KD

Median target $14 (+6%) · 5 ratings · Hold consensus

Strong Buy00%

Buy00%

Hold480%

Sell120%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Kyndryl now?

We won't decide for you. The facts: 0% of analysts rate it a buy, median target $14 (+6%), and Scotiabank (most reliable on KD, 100%) targets $15. Weigh that against valuation and volatility. This is not personalized advice.

Is it too late to invest in Kyndryl?

Not according to analysts: the median target ($14) is still +6% above the current price ($13) (most reliable on KD: Scotiabank, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Kyndryl still worth investing in?

It depends on the gap between the price ($13) and its estimated value: analysts target $14 on median (+6%), with 0% buys (most reliable on KD: Scotiabank, 100%). Cross-check with their real reliability on KD and the cautions above. Information, not advice.

What's the main risk in buying KD?

The consensus is not unanimous: of 5 ratings, 4 are neutral and 1 is a sell.

→ Go deeper: the full Kyndryl profile (consensus, analyst reliability, price target, performance).